A fee based consultancy service to developers of pharmaceuticals, biopharmaceuticals, digital health technologies and diagnostics

Our scientific advice services are uniquely positioned to:

  • help you develop evidence that demonstrates the value of your product
  • provide detailed feedback on your evidence generation plans
  • help to integrate cost-effectiveness considerations into your evidence generation plans
  • provide support from the highest calibre independent experts within the NHS and academia
  • give you access to the perspective of our patient experts
  • help companies understand health technology assessments and the perspective of decision makers.
 

Our confidential advice helps the life sciences industry develop high quality evidence generation plans that capture what matters to patients and the healthcare system.

When to use our services

You can request our advice on medicinal products as well as cell and gene therapies, medical devices and diagnostics. To get the most from our services, we recommend seeking advice prior to finalising your clinical trial/study designs, although advice can be sought in relation to your economic strategy after your trials are underway.  For more detail on timings, please see our timeline (below) and read our frequently asked questions

Medtech

  • Proof of concept, prototype phase

    Get an early insight into building an evidence base to demonstrate the value of your technology and meet the needs of HTA bodies, commissioners and payers with our META  tool©.

  • Evidence generation phase

    Identify any gaps in your evidence generation plans  and receive information on the next steps using our META tool©.

    Optimise your clinical trial/study plans by getting answers to your questions and receiving key insights through our advisory services. 

  • Adoption phase

    Identify any gaps in the existing evidence base for your technology and receive information on the next steps with the META  tool©. 

Pharmaceuticals

  • Pre-clinical / Phase 1

    Initiate early dialogue with us when your technology does not fit the conventional development paradigm and there is uncertainty around your evidence generation plans.

  • Phase 2 and 3

    Optimise your clinical trial/study plans by getting answers to your questions and receiving key insights through our advisory services.

  • Post phase 3, pre-authorisation

    Optimise your economic strategy and/or any additional clinical trial/study plans by getting answers to your questions and receiving key insights through our advisory services.

    Seek expert technical advice on the structure, transparency and overall suitability of your economic model with our PRIMA service.

  • Post-authorisation

    Optimise any further clinical trial/study plans by getting answers to your questions and receiving key insights through our advisory services.

    Seek expert technical advice on the structure, transparency and overall suitability of your economic model with our PRIMA service.